{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-005822","form_type":"8-K","ticker":"ZLAB","cik":"0001704292","company_name":"Zai Lab Ltd","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.206068+00:00","generated_at":"2026-06-18T18:24:48.456117+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zai Lab Reports Full-Year 2022 Revenue of $215M, Up 49% YoY","bullets":["Total revenue $215.0M in 2022, a 49.0% increase year-over-year; ZEJULA revenue $145.2M, up 55.2%.","Net loss narrowed to $443.3M from $704.5M in 2021; cash position $1.0B as of Dec 31, 2022.","Expects commercial profitability in 2023 and overall corporate profitability by end of 2025.","Key pipeline milestones: BLA submission for efgartigimod in gMG, NDA for repotrectinib, and initiation of KarXT bridging study in China.","Appointed Michel Vounatsos to Board and Rafael Amado as President, Global Oncology R&D."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-005822","json":"https://secwatch.observer/filing/0001628280-23-005822.json","markdown":"https://secwatch.observer/filing/0001628280-23-005822.md","text":"https://secwatch.observer/filing/0001628280-23-005822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704292/000162828023005822/0001628280-23-005822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704292/000162828023005822/zlab-20230301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T18:24:48.456117+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"faeac707555184841df3fd9d92f069bb3a9d9792","claim":"Zai Lab Ltd reported the year ended December 31, 2022 results: revenue $215.0 million.","evidence_excerpt":"ai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates – Total revenue of $215.0 million for 2022, representing a 49.0% increase y-o-y; ZEJULA ® achieved 55.2% y-o-y growth – Strong balance sheet with a cash position of $1.0 billion as of December 31, 2022 – Company to host conference call and webcast on March 2, 2023, at 8:00 a.m.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704292/000162828023005822/0001628280-23-005822-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$215.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}